IIDCA

Instituto de Investigación y Desarrollo de Ciencia Aplicada

UPDATE SEPT 2013

On September 18, 2013

Research project the effects of ImmunoFX EPHT in Mexico

The purpose of this report is to put them abreast of the advances in the research of the product ImmunoFX in Mexico.

The literature review required to conduct this study is underway. We have used the information that shows us the EPHT page, relative to the bacterium extremophiles and protein qualities focused on gene repair in situations of are.

Contained in the product ImmunoFX specific proteins are not yet characterized the literature review is as soon general. As soon as the detailed physico-chemical analysis is ready we will explore the specific qualities of the contents to justify their characteristics and therapeutic mechanisms.

However there is a critical number of studies which demonstrates the effectiveness of these proteins in both medical and veterinary treatments in diseases partners with poor repair mechanisms of genetic damage in diseased cells and a low immunity in the specialized literature.

The use of protein of extremophiles bacteria and other organisms resistant to stress in human conditions, promises a therapeutic approach that is distinct and focused on the recovery of biological dysfunctions caused by modern life and all nutritional deficiencies has led to. There is evidence that this type of proteins that provide stability to the bacterial genomes can be rescued by other non-bacterial organisms cells what would prove the effectiveness in human cells.

The application of this type of therapeutic approach also provides a different approach to conventional medicine, show the Agency as a set of highly interconnected non-trivial biological processes and systems, therefore the solutions against the disease should not be partial but systemic and consequently without unwanted side effects. The study on therapeutic applications of enzymes from extremophile bacteria promises a novel tool in the treatment of ailments that afflict our societies.

1. Shift in drug evaluation tests

- Physical stability of compound
- General physico-chemical characteristics of the compound
- Bromatografic or chemical study proximal to see the composition of the product



Instituto de Investigación y Desarrollo de Ciencia Aplicada

- Spectrophotometric titration to learn the protein component to determine its molecular weight
- Microbiological analysis
- 2. Toxicological analysis
 - In mice, rats and whose will assess where acute and sub-acute toxicity
 - Chronic toxicity will be analyzed in dogs
- 3. Realization of clinical data with various pathologies installed in 15 patients.
- 4. Study in a sample murine genetically modified to develop melanoma
- 5. We have initiated phase II of the Protocol, with a population sample of 50 women who take the recommended dose of the product from a week ago at the same time. This population sample study one day, we perform comprehensive analysis of blood and urine. Once they started the treatment they are under day-to-day clinical surveillance. Some of the individuals who are pursuing the treatment are taking a placebo.

We have started the necessary procedures for mounting experiments in three different areas, at the Faculty of chemistry, the Faculty of medicine and the Faculty of veterinary medicine of the University Of National Autonoma De Mexico, where to undertake treatment in animals and the study of samples and tissue once the treatment is finished.

The times of these procedures are standardized, however are not immediate but if fundamental to Mexican standards.